Medical technology giant Becton Dickinson & Co. announced Thursday it has reached a settlement of $22 million to end four class action lawsuits against the firm accusing the company of attempting to monopolize the hypodermic needle market. Specifically, members of the class action claimed BD of squeezing competitors out of the market by offering steep discounts on bundled hospital equipment products so long as hospitals agreed to buy the majority of their needles from BD. Further, BD was accused of giving company stock to group purchasing organizations, which determine prices set for hospitals. Court documents allege that such agreements were anticompetitive, violated antitrust law, raised prices and reduced innovation. The company announced the settlement along with its third-quarter earnings report. BD says the settlement cut share prices by 7 cents.
Featured News
Trump’s Defamation Case Against New York Times Advances in Federal Court
Nov 19, 2026 by
CPI
Musk’s xAI Faces Skeptical US Judges Over California AI Disclosure Law
Nov 19, 2026 by
CPI
Italy Ends Vorwerk Antitrust Probe After Consumer Compensation Deal
Nov 19, 2026 by
CPI
Canada Wins Court Order to Advance Gap, Old Navy Advertising Probe
Nov 19, 2026 by
CPI
Russia Orders Major Retailers to Disclose Food Pricing Data in Antitrust Review
Nov 19, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Labor Market Collusion
Nov 19, 2026 by
CPI
From Price-Fixing to Wage-Fixing: Are Labor Markets the Next Frontier of Public and Private Competition Law Enforcement?
Nov 19, 2026 by
Giulia Rurali & Carsten Krüger
Damage Estimation and Labor Market Collusion
Nov 19, 2026 by
Louis D. Pape
Recent Developments of Labor Market Collusion in the EU: The Dialogue Between Delivery Hero and Tondela
Nov 19, 2026 by
Catarina Vieira Peres & Rita Ferreira Gomes
Enforcement in Labor Collusion and Monopsony: Trends and Challenges
Nov 19, 2026 by
Leyla Karakas & Anna Meyendorff